Acetylated Nanoformulation of N‐(4‐Hydroxyphenyl)‐4‐Oxoretinamide Inhibits EZH2‐Mediated Epigenetic Repression in Neuroblastoma
Small · 2026-05 · 22 (25)
DOI: 10.1002/smll.202512024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 10.03.2026. Verfasst von Boddu Mrunalini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Biology Unit, Institute of Nano Science and Technology, Mohali, Punjab, India. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Neuroblastoma, Epigenetic Repression, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Department of Biotechnology, Indian Council of Medical Research, Government of India for providing partial.
Abstract (Originalsprache)
Neuroblastoma (NB) is a highly malignant pediatric extracranial tumor with genetic and epigenetic factors influencing its pathogenesis. Key genetic contributors include germline mutations in ALK and PHOX2B, as well as somatic amplification of MYCN. The epigenetic regulator EZH2, a histone methyltransferase of the PRC2 complex, is overexpressed in NB and linked to poor prognosis in advanced cases. Targeting EZH2 offers a promising therapeutic approach due to its role in tumor proliferation, survival, and maintenance of undifferentiated states. This study explores the use of acetylated human serum albumin nanoparticles (HSANPs) loaded with 4O4HPR for epigenetic therapy in NB, tested in vitro and in vivo using nude mice xenograft models. The nanoparticles enter cells via clathrin‐mediated endocytosis and induce G2‐M cell cycle arrest, mitochondrial depolarization, and the production of reactive oxygen species, which activate Caspase 3 and trigger apoptosis. Mechanistic studies show increased p53 acetylation, stabilizing p53 and inhibiting EZH2's epigenetic silencing. Chromatin Immunoprecipitation reveals the disruption of EZH2 binding to the E‐Cadherin promoter, which suppresses cell migration and EMT‐like transition. Western blotting confirms upregulation of epithelial and downregulation of mesenchymal markers, with inhibited wound closure in SH‐SY5Y cells. This nanotherapy disrupts EZH2‐E‐Cadherin interaction, offering novel translational potential for NB treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemical Biology Unit, Institute of Nano Science and Technology, Mohali, Punjab, India.
ORCID-Profile: Surajit Karmakar
Förderung
- Department of Biotechnology
- Indian Council of Medical Research
- Government of India for providing partial
- Department of Health Research, India
- Department of Biotechnology, Government of West Bengal
Zitieren
APA
Mrunalini, B., Dev, A., & Karmakar, S. (2026). Acetylated Nanoformulation of N‐(4‐Hydroxyphenyl)‐4‐Oxoretinamide Inhibits EZH2‐Mediated Epigenetic Repression in Neuroblastoma. Small, 22(25). https://doi.org/10.1002/smll.202512024
Vancouver
Mrunalini B, Dev A, Karmakar S. Acetylated Nanoformulation of N‐(4‐Hydroxyphenyl)‐4‐Oxoretinamide Inhibits EZH2‐Mediated Epigenetic Repression in Neuroblastoma. Small. 2026;22(25). doi:10.1002/smll.202512024
BibTeX
@article{Mrunalini2026,
author = {Mrunalini, Boddu and Dev, Atul and Karmakar, Surajit},
title = {Acetylated Nanoformulation of N‐(4‐Hydroxyphenyl)‐4‐Oxoretinamide Inhibits EZH2‐Mediated Epigenetic Repression in Neuroblastoma},
journal = {Small},
year = {2026},
volume = {22},
number = {25},
doi = {10.1002/smll.202512024}
}
EUVIMED